AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21366734 — intervention group
Group type: EXPERIMENTAL
Intervention: Second surveillance test late attendance
Number of subjects: 2166
Study 20298651 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based formula with 10% sucrose
Number of subjects: 11
Study 20298651 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula with 10% sucrose
Number of subjects: 11
Study 20298651 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based formula without sucrose
Number of subjects: 11
Study 20298651 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula without sucrose
Number of subjects: 11
Study 20298651 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose solution
Number of subjects: 11
Study 20298651 — intervention group
Group type: COMPARATOR
Intervention: Distilled and deionized water
Number of subjects: 11
Study 17381714 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b plus ribavirin
Number of subjects: 121
Study 17381714 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha-2b plus ribavirin
Number of subjects: 121
Study 17381714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 121
Study 16283812 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of intrusive force to the maxillary incisors
Number of subjects: 20
Study 16283812 — intervention group
Group type: COMPARATOR
Intervention: 80 g of intrusive force to the maxillary incisors
Number of subjects: 20
Study 12110412 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 140
Study 12110412 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 140
Study 11011336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg
Number of subjects: 164
Study 11011336 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 164
Study 8780288 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 27
Study 8780288 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 27
Study 8780288 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 27
Study 1473517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation
Number of subjects: 66
Study 1473517 — intervention group
Group type: COMPARATOR
Intervention: Control (no sodium supplementation)
Number of subjects: 66
Study 6365015 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine plus haloperidol
Number of subjects: 43
Study 6365015 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus haloperidol
Number of subjects: 43
Study 29783863 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg and subcutaneous sumatriptan 12 mg
Number of subjects: 34
Study 29783863 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo and subcutaneous sumatriptan 12 mg
Number of subjects: 34
Study 28277015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 32 min of treadmill HIIT alternating 3 min at 60-70% of HRmax with 1 min at 80-90% of HRmax
Number of subjects: 27
Study 28277015 — intervention group
Group type: COMPARATOR
Intervention: Steady-State (SS) exercise - 32 continuous minutes of treadmill walking at 60-70% of HRmax
Number of subjects: 27
Study 28277015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 27
Study 28277015 — intervention group
Group type: COMPARATOR
Intervention: Steady-State (SS) exercise
Number of subjects: 27
Study 28689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 6mg
Number of subjects: 354
Study 28689624 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 100µg
Number of subjects: 354
Study 25600421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin added to usual type 2 diabetes care
Number of subjects: 14724
Study 25600421 — intervention group
Group type: COMPARATOR
Intervention: Usual type 2 diabetes care (placebo)
Number of subjects: 14724
Study 23567779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model including narrative and codified data
Number of subjects: 600
Study 23567779 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural language processing narrative terms added to the final model
Number of subjects: 600
Study 21975206 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg MBP8298, given by IV injection once every 6 months for 2 years
Number of subjects: 612
Study 21975206 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given by IV injection once every 6 months for 2 years
Number of subjects: 612
Study 18297821 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqigushen Capsule combined with levofloxacin
Number of subjects: 180
Study 18297821 — intervention group
Group type: COMPARATOR
Intervention: Yiqigushen Capsule only
Number of subjects: 180
Study 17137405 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI (160 microg/4.5 microg x two inhalations)
Number of subjects: 596
Study 17137405 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI + formoterol DPI
Number of subjects: 596
Study 17137405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study 12706287 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom (FC) intervention
Number of subjects: 315
Study 12706287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 315
Study 11213741 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic irrigation through canaliculi
Number of subjects: 76
Study 11213741 — intervention group
Group type: COMPARATOR
Intervention: Nasolacrimal system probing
Number of subjects: 76
Study 11213741 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic irrigation with isolated microorganisms
Number of subjects: 76
Study 11213741 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic irrigation with no isolated microorganisms
Number of subjects: 76
Study 11213741 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of success rates between groups with and without growth
Number of subjects: 76
Study 11213741 — intervention group
Group type: COMPARATOR
Intervention: Comparison of success rates between irrigation and probing
Number of subjects: 76
Study 9310603 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest salt restriction (5 g salt intake)
Number of subjects: 47
Study 9310603 — intervention group
Group type: COMPARATOR
Intervention: Normal salt intake (10 g salt intake)
Number of subjects: 47
Study 9310603 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest sodium restriction
Number of subjects: 47
Study 9310603 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between normotensive and hypertensive participants
Number of subjects: 47
Study 7870975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium in addition to haloperidol
Number of subjects: 21
Study 7870975 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to haloperidol
Number of subjects: 21
Study 7870975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium/haloperidol treatment
Number of subjects: 21
Study 7870975 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 21
Study 3526570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafcillin plus rifampin
Number of subjects: 26
Study 3526570 — intervention group
Group type: COMPARATOR
Intervention: Nafcillin
Number of subjects: 26
Study 30041929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalantercept, administered subcutaneously at 1.2 mg/kg every 3 weeks until disease progression or unacceptable toxicity
Number of subjects: 30
Study 27597278 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic irradiation with concomitant weekly paclitaxel (experimental arm)
Number of subjects: 151
Study 27597278 — intervention group
Group type: COMPARATOR
Intervention: Thoracic irradiation without concurrent chemotherapy (control arm)
Number of subjects: 151
Study 27597278 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of 5 trials (n=866)
Number of subjects: 151
Study 25243839 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350‐electrolyte solution (PEG), 4‐L dose
Number of subjects: 50
Study 25243839 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care lactulose
Number of subjects: 50
Study 23522096 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose of levothyroxine (target range 4.1 to 8.0 mU/L)
Number of subjects: 50
Study 23522096 — intervention group
Group type: COMPARATOR
Intervention: Standard levothyroxine replacement (target range 0.4 to 4.0 mU/L)
Number of subjects: 50
Study 20609969 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (2 mg, once-a-week injection)
Number of subjects: 456
Study 20609969 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (once-daily injection, starting dose 10 IU)
Number of subjects: 456
Study 20609969 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 456
Study 20609969 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 456
Study 18835539 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids 8 g/day (EAA group; n=21)
Number of subjects: 38
Study 18835539 — intervention group
Group type: COMPARATOR
Intervention: No supplements (controls; n=17)
Number of subjects: 38
Study 16809874 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research intervention including multimedia campaign, lay health worker outreach, Vietnamese Pap clinic with patient navigation, registry and reminder system, continuing medical education for Vietnamese physicians, and restoring a Breast and Cervical Cancer Control Program site.
Number of subjects: 0
Study 16809874 — intervention group
Group type: COMPARATOR
Intervention: Comparison community (Harris County, Texas)
Number of subjects: 0
Study 14669420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (LDA, 75 mg daily)
Number of subjects: 148
Study 14669420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (20 g daily)
Number of subjects: 148
Study 14669420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid and low molecular weight heparin simultaneously
Number of subjects: 148
Study 14669420 — intervention group
Group type: COMPARATOR
Intervention: Isolated occurrence of lupus anticoagulant antibodies
Number of subjects: 148
Study 14669420 — intervention group
Group type: COMPARATOR
Intervention: Occurrence of anticardiolipin antibodies
Number of subjects: 148
Study 14669420 — intervention group
Group type: COMPARATOR
Intervention: Anticardiolipin antibodies with lupus anticoagulant antibodies simultaneously
Number of subjects: 148
Study 11789227 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiayanxiao plus tapazole
Number of subjects: 43
Study 11789227 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus tapazole
Number of subjects: 43
Study 8819063 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute arthroscopic lavage within 10 days
Number of subjects: 30
Study 8819063 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 30
Study 7987976 — intervention group
Group type: EXPERIMENTAL
Intervention: ADR-529 (600-1000 mg/m2) with epirubicin (60-100 mg/m2), cyclophosphamide (600 mg/m2), 5-fluorouracil (600 mg/m2), and tamoxifen (30 mg)
Number of subjects: 82
Study 7987976 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (60-100 mg/m2)
Number of subjects: 82
Study 7987976 — intervention group
Group type: EXPERIMENTAL
Intervention: ADR-529 (600-1000 mg/m2)
Number of subjects: 82
Study 3166194 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3% sodium fluoride varnish Duraphat, applied three times
Number of subjects: 120
Study 3166194 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% sodium fluoride varnish Duraphat, applied three times
Number of subjects: 120
Study 3166194 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% NaF solution, applied nine times
Number of subjects: 120
Study 3166194 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3% sodium fluoride varnish Duraphat, applied once
Number of subjects: 120
Study 3166194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 31400759 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/relebactam
Number of subjects: 47
Study 31400759 — intervention group
Group type: COMPARATOR
Intervention: Colistin+imipenem
Number of subjects: 47
Study 29958616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral closure of the tonsillar fossa
Number of subjects: 132
Study 29958616 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral closure of the tonsillar fossa
Number of subjects: 132
Study 29958616 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of the tonsillar fossa
Number of subjects: 132
Study 29958616 — intervention group
Group type: COMPARATOR
Intervention: Control group (closure methods)
Number of subjects: 132
Study 27540904 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 0.25 g/kg (Group A)
Number of subjects: 124
Study 27540904 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 0.5 g/kg (Group B)
Number of subjects: 124
Study 27540904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 1.0 g/kg (Group C)
Number of subjects: 124
Study 27540904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 1.5 g/kg (Group D)
Number of subjects: 124
Study 28186023 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS messaging to patients and their medical homes (Reports)
Number of subjects: 7146
Study 28186023 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS messaging to patients, their medical homes, and their care managers (Reports+)
Number of subjects: 7146
Study 28186023 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 7146
Study 24247662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate personal protective equipment (PPE)
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Lack of adequate PPE
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Fear of family members becoming ill
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Assignment to direct care of a flu patient
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Colleague quarantined or died of pandemic flu
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Fear of family members dying of pandemic flu
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Personal illness
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Family member or loved one sick at home
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Lack of written family protection plan
Number of subjects: 735
Study 24247662 — intervention group
Group type: COMPARATOR
Intervention: Incentives offered (antiviral medication, vaccine, double pay, free room and board)
Number of subjects: 735
Study 24247662 — intervention group
Group type: EXPERIMENTAL
Intervention: General willingness to work during a flu pandemic
Number of subjects: 735
Study 24247662 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived level of threat from flu pandemic
Number of subjects: 735
Study 21364273 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 μg daily + Alendronate 70 mg weekly + 500 mg calcium daily
Number of subjects: 279
Study 21364273 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Alendronate 70 mg weekly + 500 mg calcium daily
Number of subjects: 279
Study 21364273 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol + Alendronate
Number of subjects: 279
Study 21364273 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Alendronate
Number of subjects: 279
Study 19961374 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + DFDBA
Number of subjects: 24
Study 19961374 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 24
Study 15494330 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extracorporeal shock wave therapy (2000 pulses, energy flux density 0.03-0.17 mJ/mm(2))
Number of subjects: 60
Study 15494330 — intervention group
Group type: COMPARATOR
Intervention: Sham extracorporeal shock wave therapy
Number of subjects: 60
Study 15494330 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extracorporeal shock wave therapy
Number of subjects: 60
Study 11684941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir or nelfinavir/saquinavir
Number of subjects: 16
Study 11684941 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir
Number of subjects: 16
Study 9515521 — intervention group
Group type: COMPARATOR
Intervention: Single-dose regimen of ticarcillin 3.0 g/clavulanate 0.1 g (Timentin)
Number of subjects: 302
Study 9515521 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose regimen of ticarcillin 3.0 g/clavulanate 0.1 g (Timentin)
Number of subjects: 302
Study 8695969 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.30 mg/day plus oral ipriflavone 200 mg tris in die at meals (group C)
Number of subjects: 83
Study 8695969 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus conjugated equine estrogens 0.30 mg/day (group B)
Number of subjects: 83
Study 8695969 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (group A)
Number of subjects: 83
Study 2085984 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (5 days treatment)
Number of subjects: 62
Study 2085984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (single dose)
Number of subjects: 62
Study 2085984 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 62
Study 2085984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol
Number of subjects: 62
Study 289691 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized self‐instructional (ACORDE) format
Number of subjects: 0
Study 289691 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture method
Number of subjects: 0
Study 30472886 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive perception of insulin treatment
Number of subjects: 80
Study 30472886 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigmatization
Number of subjects: 80
Study 30472886 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing others about one's type 1 diabetes
Number of subjects: 80
Study 30472886 — intervention group
Group type: EXPERIMENTAL
Intervention: Only using insulin when alone in public places
Number of subjects: 80
Study 31115304 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV vaccine
Number of subjects: 0
Study 27101422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg twice daily
Number of subjects: 24
Study 27101422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol 60 mg twice daily
Number of subjects: 24
Study 27101422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol 90 mg twice daily
Number of subjects: 24
Study 26530491 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 120
Study 26530491 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav + INS
Number of subjects: 120
Study 26530491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23224207 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective intra‐aortic balloon pump (IABP) support during PCI
Number of subjects: 301
Study 23224207 — intervention group
Group type: COMPARATOR
Intervention: PCI without planned IABP support
Number of subjects: 301
Study 21985332 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple's risk reduction intervention combined with evidence-based medication adherence intervention
Number of subjects: 240
Study 21985332 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 240
Study 18840576 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm priming solution at 36 degrees C
Number of subjects: 40
Study 18840576 — intervention group
Group type: COMPARATOR
Intervention: Cold priming solution at 20 degrees C
Number of subjects: 40
Study 17062362 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxyribonucleotidum in addition to routine treatment
Number of subjects: 88
Study 17062362 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 88
Study 14663305 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser pointer visual field screening (LVF)
Number of subjects: 90
Study 14663305 — intervention group
Group type: COMPARATOR
Intervention: Conventional confrontation visual field (CVF)
Number of subjects: 90
Study 14663305 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated perimetry (HVF)
Number of subjects: 90
Study 10896369 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental agent
Number of subjects: 160
Study 10896369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 2014035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine (1 mg/kg loading dose, followed by 0.25 mg/kg at 8 and 16 hours after resuscitation)
Number of subjects: 520
Study 2014035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 2014035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 520
Study 7152766 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐min vigorous, aerobic exercise session 4 days per week for 8 months
Number of subjects: 59
Study 7152766 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained normal daily activities including a 1 day per week physical education class for 8 months
Number of subjects: 59
Study 31230889 — intervention group
Group type: EXPERIMENTAL
Intervention: LAUNCH (Learning about Activity and Understanding Nutrition for Child Health)
Number of subjects: 100
Study 31230889 — intervention group
Group type: EXPERIMENTAL
Intervention: LAUNCH caregivers
Number of subjects: 100
Study 29869601 — intervention group
Group type: EXPERIMENTAL
Intervention: Anopheles salivary biomarker (gSG6-P1)
Number of subjects: 9000
Study 29869601 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP-119 antigen
Number of subjects: 9000